Haduvio Opportunity Positions Trevi (TRVI) for Multibagger Gains, Says Morgan Stanley

Trevi Therapeutics Inc. (NASDAQ:TRVI) is one of the best multibagger stocks to invest in right now. On August 21, Morgan Stanley’s Judah Frommer initiated coverage of the stock with an Overweight rating and an $18 price target. The Overweight call is based on Haduvio, the company’s extended-release formulation of nalbuphine, which is being developed as a treatment for chronic cough. Haduvio Opportunity Positions Trevi (TRVI) for Multibagger Gains, Says Morgan Stanley Frommer said Haduvio stands out in a ...